Autoimmune kidney disease occurs when the immune system mistakenly attacks the kidneys’ own tissues, triggering inflammation that can progressively destroy the organ’s filtering capacity. Rather than being a single condition, it is an umbrella term covering several distinct diseases, from lupus nephritis to IgA nephropathy to anti-GBM disease. The common thread is that immune proteins or cells meant to defend the body instead cause harm to kidney structures, and the damage often centers on the glomeruli, the tiny filtering units responsible for cleaning blood.
How the Immune System Damages the Kidneys
Your kidneys filter roughly 50 gallons of blood a day through glomeruli, each one a knot of tiny blood vessels surrounded by specialized cells and a thin membrane. That membrane is where most autoimmune kidney damage starts. In many of these diseases, clusters of antibodies bound to their target (called immune complexes) get physically stuck in the glomerular filtering barrier because of their size and electrical charge.1PubMed Central. The role of the immune system in kidney disease Once trapped, these complexes trigger a chain reaction of inflammation that damages surrounding tissue.
Sometimes the immune complexes form elsewhere in the bloodstream and drift into the kidney. Other times, they assemble right at the glomerular membrane itself. In lupus, for instance, fragments of dying cells can lodge in the membrane, and autoantibodies then bind to those fragments in place, building immune complexes on-site.1PubMed Central. The role of the immune system in kidney disease Regardless of how the complexes form, the result is the same: the complement system activates, mitochondrial function in kidney tubule cells is disrupted, and the tissue starts to scar.2PubMed Central. Proteomic analysis of laser captured tubular tissues reveals complement activation and mitochondrial dysfunction in autoimmune related kidney diseases Researchers have identified specific complement proteins (like C3, C4, and complement factor B) that are consistently altered across multiple autoimmune kidney diseases, suggesting a shared damage pathway even though the initial trigger differs from disease to disease.
Major Types of Autoimmune Kidney Disease
Although these diseases share immune-mediated injury, they differ in which antibody goes wrong, which part of the kidney is attacked, and how aggressively the disease progresses. The most common forms are worth knowing individually because their treatment and outlook can be quite different.
Lupus Nephritis
Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE), a disease in which autoantibodies attack many organs. Kidney involvement is one of the most serious complications of lupus. The severity ranges widely and is formally classified into six classes based on biopsy findings. Class I and II involve only the mesangium, the tissue between glomerular capillaries, with immune deposits and varying degrees of cell overgrowth. Class III and IV are more aggressive forms where inflammation hits a larger proportion of the glomeruli, and Class V involves a membranous pattern. Class VI represents advanced scarring.3PubMed. The classification of glomerulonephritis in systemic lupus erythematosus revisited Importantly, immune complex deposits in lupus nephritis are not confined to the glomeruli. They can also show up in the tubulointerstitial space, the tissue surrounding the kidney’s tubules, and this often accompanies interstitial inflammation.4PubMed. Extraglomerular immune complex deposition in lupus nephritis
IgA Nephropathy
IgA nephropathy is the most common form of glomerulonephritis worldwide. In this disease, a portion of the body’s IgA1 antibodies are produced with abnormal sugar chains on their surface, leaving certain residues exposed that the immune system then treats as foreign. The body makes autoantibodies against this defective IgA1, and the resulting immune complexes deposit in the kidney’s mesangium.5PubMed Central. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy Recent work has shown that a receptor on mesangial cells pulls the abnormal IgA1 into the cell’s lysosomes, where it forms clumps that cannot be digested, eventually disrupting the cell’s internal cleanup machinery and sparking inflammation.6Nature Communications. Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy IgA nephropathy often progresses slowly, with some people losing kidney function over decades, while others progress faster depending in part on the level of circulating autoantibodies against the defective IgA1.
Membranous Nephropathy
In primary membranous nephropathy, the immune system produces autoantibodies against a protein called the phospholipase A2 receptor (PLA2R), which sits on the surface of podocytes, the specialized cells that wrap around glomerular capillaries and help form the filtration barrier.7PubMed Central. Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch When anti-PLA2R antibodies bind their target, immune deposits form beneath the podocytes and cause the glomerular basement membrane to thicken, leading to heavy protein leakage into the urine.8PubMed Central. Structural determinants of the dominant conformational epitopes of phospholipase A2 receptor in primary membranous nephropathy Because anti-PLA2R antibody levels can be measured with a blood test, this is one of the few autoimmune kidney diseases where doctors can monitor disease activity without repeated biopsies.
ANCA-Associated Vasculitis
ANCA-associated vasculitis (AAV) is an autoimmune disease in which antibodies target proteins inside neutrophils, a type of white blood cell. These anti-neutrophil cytoplasmic autoantibodies (ANCAs) typically target either myeloperoxidase (MPO) or proteinase 3 (PR3). The disease inflames small blood vessels throughout the body, and the kidneys are frequently hit hard. When neutrophils die, they release web-like structures of DNA coated with MPO and PR3, called neutrophil extracellular traps (NETs). These NETs have been found deposited in kidney tissue of patients with AAV and are thought to both drive the inflammation and serve as a source for continued ANCA production.9PubMed. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA Biopsy studies have shown NET components deposited around areas of fibrinoid necrosis in the glomeruli and along artery walls within the kidney.10Clinical Kidney Journal. Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis
Anti-GBM Disease (Goodpasture’s Disease)
Anti-GBM disease is rare but dramatic. The autoantibodies attack a specific component of collagen IV in the glomerular basement membrane itself. The principal target is the alpha-3 chain of type IV collagen, and because this collagen type is also found in the lungs, patients can develop both kidney failure and lung hemorrhage.11PubMed Central. Goodpasture’s autoimmune disease – A collagen IV disorder Research has confirmed that reactivity to the alpha-3 chain is both necessary and sufficient for the disease to occur.12PubMed. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome In patients with active disease, autoantibodies against both the alpha-3 and alpha-5 monomers have been found bound in kidney and lung tissue.13PubMed Central. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis Without rapid treatment, anti-GBM disease can destroy kidney function within days to weeks.
Symptoms and Warning Signs
One of the tricky things about autoimmune kidney disease is that early stages often produce no obvious symptoms. The kidneys have enormous reserve capacity, and significant damage can accumulate before you feel anything. When symptoms do appear, they tend to reflect either protein leaking into the urine or a general decline in filtering ability. Proteinuria, which means excess protein in the urine, is a hallmark of glomerular damage.14PubMed Central. Proteinuria precedes podocyte abnormalities in Lamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier You might notice foamy urine, swelling in the ankles and around the eyes (from fluid retention caused by protein loss), or urine that looks darker than normal, sometimes tea-colored if blood is present.
In more aggressive forms like anti-GBM disease or severe ANCA vasculitis, symptoms can appear suddenly. Blood in the urine, rapidly rising blood pressure, fatigue, nausea, and decreased urine output can all signal a rapid loss of kidney function. ANCA vasculitis, because it affects blood vessels beyond the kidneys, may also cause joint pain, skin rashes, sinus problems, or coughing up blood. Lupus nephritis often appears alongside the broader systemic symptoms of lupus, including joint pain, rashes, and fatigue. IgA nephropathy, by contrast, may announce itself only with intermittent episodes of visible blood in the urine, sometimes triggered by an upper respiratory infection.
How Autoimmune Kidney Disease Is Diagnosed
Diagnosis usually begins with simple blood and urine tests. Kidney function markers, particularly the estimated glomerular filtration rate (eGFR), cystatin C levels, and urine albumin, are significantly affected by the presence of autoantibodies. Autoantibodies are also more frequent in people with severe kidney damage, which is why tracking both renal markers and autoantibody levels together can help catch kidney involvement earlier.15PubMed Central. Evaluation of renal markers in systemic autoimmune diseases Blood tests for specific autoantibodies, such as anti-PLA2R for membranous nephropathy, ANCA for vasculitis, or anti-GBM antibodies, can point toward a specific diagnosis before a biopsy is even done.
A kidney biopsy, however, remains the gold standard. The tissue sample is examined under three different microscopy techniques: standard light microscopy, immunofluorescence (which reveals where immune proteins have deposited), and electron microscopy. Electron microscopy is especially valuable for autoimmune kidney disease because it can locate deposits at the ultrastructural level, distinguishing between subepithelial, subendothelial, and mesangial locations, which is critical for accurate classification of diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy.16PubMed Central. Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters In a large study of over 2,000 kidney biopsies, electron microscopy played an important role in reaching the correct diagnosis in about half of patients, preventing misdiagnosis in many cases.17Journal of Renal Injury Prevention. An overview on the diagnostic role of electron microscopy for kidney diseases, study of 2006 native kidney biopsies in Iran
Researchers are also working on non-invasive alternatives. Studies on urinary biomarker panels in lupus nephritis have developed algorithms using combinations of urinary markers that can predict the degree of inflammatory activity and chronic damage in the kidney with over 88% specificity and 93% accuracy, potentially reducing the need for repeat biopsies in some patients.18BMJ. Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis These tools are not yet standard practice, but they represent a promising direction.
Genetic and Environmental Triggers
No single gene causes autoimmune kidney disease, but genetics load the gun. In lupus, large-scale genomic studies have identified dozens of risk loci that converge on a handful of immune pathways: antigen presentation, type I interferon signaling, B-cell activation, and immune complex clearance. Key genes include HLA-DRB1, IRF5, STAT4, and several Fc-gamma receptor variants.19PubMed Central. Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa Most of these risk variants contribute to systemic immune dysregulation rather than kidney-specific susceptibility, which helps explain why lupus can damage many organs. A few loci, however, have been linked specifically to kidney involvement, and APOL1 G1/G2 risk variants are associated with worse kidney outcomes among individuals of African ancestry.19PubMed Central. Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa
Environmental triggers also matter. Infections can set off or worsen autoimmune kidney disease, likely by activating the immune system in ways that break self-tolerance. Ultraviolet light exposure, smoking, certain medications, and hormonal factors (lupus is far more common in women of childbearing age) are all recognized contributors. For IgA nephropathy, upper respiratory or gastrointestinal infections often precede flares of visible blood in the urine, and there is evidence that mucosal immune responses gone wrong play a role in producing the aberrant IgA1 that drives the disease.
Treatment Approaches
Treatment for autoimmune kidney disease has two overlapping goals: suppress the immune attack and protect the kidneys from further damage. The specific strategy depends heavily on which disease you have and how severe it is.
Immunosuppressive Therapy
For lupus nephritis, the backbone of treatment is immunosuppression. Standard first-line regimens include either mycophenolate mofetil or cyclophosphamide, typically combined with glucocorticoids.20PubMed. Lupus nephritis Cyclophosphamide remains widely used for severe cases despite being an older drug, in part because no newer agent has fully replaced it for the most aggressive forms of the disease.21PubMed Central. Revisited Cyclophosphamide in the Treatment of Lupus Nephritis These treatments are not uniformly effective, though, and side effects from prolonged steroid use and immunosuppression remain a real concern.
Biologic Therapies
Newer biologic drugs target specific parts of the immune system. Belimumab, which blocks a protein called B-lymphocyte stimulator, has shown benefit when added to standard treatment for lupus nephritis. It reduced the risk of kidney-related events or death, lowered the rate of lupus nephritis flares, and slowed the decline in kidney filtration rate over time.22PubMed. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis It worked best in patients with proliferative disease and moderate protein loss, but was less effective in those with very heavy proteinuria or certain deposit patterns.
B-cell depletion is another approach. Rituximab, which eliminates B cells by targeting their CD20 surface marker, has been used for refractory cases. When combined with belimumab or telitacicept (which targets a different B-cell survival signal), results have been encouraging. In one cohort, about 80% of patients with refractory lupus nephritis achieved remission on one of these combinations.23PubMed. The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis Obinutuzumab, a newer anti-CD20 antibody designed to achieve deeper B-cell depletion, showed significantly higher complete renal response rates compared to placebo in a phase III trial (about 46% vs. 33%), and has been approved for use with mycophenolate mofetil.24PubMed Central. The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities
For ANCA-associated vasculitis, an especially promising development is avacopan, a drug that blocks the C5a complement receptor. In a phase III trial, patients with kidney involvement who received avacopan showed greater improvement in kidney filtration rate compared to those on standard prednisone therapy. By one year, the avacopan group gained about 7.3 mL/min in eGFR versus about 4.1 for the prednisone group. The benefit was most dramatic in patients who started with the worst kidney function: those with stage 4 kidney disease gained roughly 13.7 mL/min compared to 8.2 in the prednisone group.25Nephrology Dialysis Transplantation. FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE Avacopan’s ability to replace long-term steroids is particularly appealing, since chronic prednisone use carries its own burden of diabetes, bone loss, and infections.26PubMed. Avacopan for the Treatment of ANCA-Associated Vasculitis
Kidney-Protective Medications
Beyond immunosuppression, protecting residual kidney function matters. Drugs that block the renin-angiotensin-aldosterone system (RAAS), such as ACE inhibitors and angiotensin receptor blockers, are standard for reducing proteinuria and slowing progression. More recently, SGLT2 inhibitors, originally developed for diabetes, have shown broad kidney-protective effects in chronic kidney disease with proteinuria, including autoimmune forms. Large studies have repeatedly demonstrated their renoprotective benefit when added to RAAS blockade.27PubMed Central. SGLT-2 inhibitors: new horizons for rheumatologists This class of drugs is increasingly seen as a useful add-on for patients with autoimmune glomerulonephritis who have persistent proteinuria despite immunosuppressive treatment.
Diet and Lifestyle in Kidney Protection
Medications get the most attention, but what you eat can meaningfully affect how fast kidney disease progresses. In people with chronic kidney disease, adherence to a Mediterranean-style diet is associated with slower disease progression, fewer complications like high phosphorus levels and metabolic acidosis, and reduced production of inflammatory compounds and uremic toxins compared to a typical Western diet.28PubMed. Mediterranean Diet for Cardiovascular Risk Reduction in Chronic Kidney Disease Given that cardiovascular disease is the leading cause of death in people with chronic kidney disease, the cardiovascular protection of this dietary pattern is an additional practical benefit. Blood pressure control, maintaining a healthy weight, and avoiding nephrotoxic medications (including some over-the-counter painkillers) are also important. None of this replaces immunosuppressive therapy, but it helps preserve whatever kidney function remains.
When Kidneys Fail and Transplantation Considerations
Despite treatment, some patients with autoimmune kidney disease progress to end-stage kidney disease (ESKD) and need dialysis or transplantation. The outcomes in this situation are not quite the same as for people who reach ESKD from other causes. In a study of patients with lupus nephritis who progressed to ESKD, the five-year dialysis survival rate was about 69%, worse than for matched patients with other causes of kidney failure. Transplant survival was also lower on an individual level, though interestingly, graft survival itself, meaning how long the transplanted kidney lasted, was comparable.29Kidney International. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis The difference in patient survival likely reflects the ongoing burden of systemic autoimmune disease beyond the kidneys.
For those on dialysis, studies comparing peritoneal dialysis and hemodialysis in lupus patients have found comparable mortality rates between the two approaches, suggesting that the choice can be individualized based on lifestyle, access, and patient preference rather than one modality being clearly superior.30PubMed Central. Peritoneal dialysis in lupus nephritis: comparative outcomes vs. hemodialysis, risk stratification, and modality selection framework
For ANCA vasculitis patients on dialysis, disease relapses remain a concern. In one long-term follow-up, the relapse rate was roughly 0.24 per patient per year, though remission was achievable in the vast majority of those relapses.31PubMed. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener’s granulomatosis
Disease Recurrence After Transplantation
One of the difficult realities of autoimmune kidney disease is that a new kidney does not necessarily mean a clean slate. Because the underlying immune dysfunction persists, the autoimmune process can attack the transplanted organ too. In patients with autoimmune kidney disease, post-transplant complications include disease recurrence, infections, malignancies from lifelong immunosuppression, and immune dysregulation.32PubMed. Immune rehabilitation after renal transplantation in autoimmune diseases: Balancing immunosuppression and risk of complications
Recurrence rates vary by disease. In a study of transplant recipients with focal segmental glomerulosclerosis (FSGS) driven by autoantibodies against podocyte proteins, early recurrence after transplant occurred in 83% of those carrying the autoantibodies, compared to just 5% of those without them.33PubMed. Anti-podocin and Anti-KIRREL1 Antibodies and Steroid Resistance, FSGS, and Disease Recurrence after Transplantation in Autoimmune Podocytopathies For ANCA vasculitis, recurrence in the graft is less common but can be devastating when it occurs. In one institutional review of six transplant recipients with ANCA-related ESKD, one patient (about 17%) experienced recurrence early after transplant, with crescentic glomerulonephritis confirmed on biopsy.34PubMed Central. Recurrence of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis Following Kidney Transplantation: A Case Report With an Institutional Registry Review From Saudi Arabia
Personalized approaches to managing transplant patients with autoimmune kidney disease are an active area of research. The hope is that monitoring specific biomarkers in the period around transplantation, and tailoring immunosuppression accordingly, could reduce recurrence and improve long-term graft performance. For now, transplant teams weigh the risk of disease recurrence against the significant survival advantage that a functioning transplant offers over long-term dialysis, and most patients with autoimmune kidney disease are considered reasonable transplant candidates once their disease has been in remission for a sustained period.